Minimed 780G System

The MiniMed 780G System is an advanced automated insulin delivery (AID) device designed to simplify diabetes management for individuals with type 1 diabetes. Manufactured by Medtronic, a global leader in medical technology, the system integrates a smart insulin pump with continuous glucose monitoring (CGM) to deliver precise, automated insulin doses. Medtronic has been at the forefront of medical innovation for over 70 years, providing trusted solutions in diabetes care. As of 2025, the system also has a U.S. indication for adults with insulin-requiring type 2 diabetes, expanding who can benefit from automation.

Specifications

Size and Weight: Compact and lightweight for easy portability.
Cartridge Size: Holds up to 300 units of insulin, suitable for extended use.
Basal Rates: Fully customizable to individual needs.
Bolus Delivery: Precise dosing for carbohydrate intake and real-time glucose levels, including automated correction boluses when needed.
Water Resistance: Rated IPX8, enabling immersion in water up to 12 feet for 24 hours.

How the Minimed 780G System Delivers Insulin

The system uses Medtronic’s SmartGuard™ technology to automatically adjust insulin delivery every five minutes based on CGM readings. This automation helps users stay within their glucose targets, reducing the risk of both highs (hyperglycemia) and lows (hypoglycemia). Additionally, its Meal Detection™ feature can automatically deliver correction doses if meal boluses are missed or underestimated. These “auto-corrections” occur about every five minutes and are influenced by user settings such as target glucose and Active Insulin Time (AIT).

The Science Behind the Algorithm

The hybrid closed-loop algorithm powering the MiniMed™ 780G System was developed by Medtronic with input from extensive clinical trials and real-world users. It adapts to the unique needs of each user by continuously analyzing CGM trends, recent insulin delivery patterns, and carbohydrate entries. In practice, selecting an appropriate target (see below) and AIT (commonly 2–8 hours) meaningfully affects how assertively the system corrects highs after meals.

Target Glucose Levels

The 780G allows users to set a glucose target as low as 100 mg/dL (5.6 mmol/L). Additional target options include 110 mg/dL and 120 mg/dL. These can be adjusted with your care team to balance tight control and hypoglycemia risk. For physical activities, users can choose the 120 mg/dL target or other strategies to help maintain safe glucose levels during exercise. The AIT setting (typically 2–8 hours) also influences how often and how strongly the system gives auto-corrections.

FDA Approval

The MiniMed 780G received FDA clearance in April 2023 for individuals aged 7 years and older with type 1 diabetes. In 2025, the U.S. indication expanded to include adults (18+) with insulin-requiring type 2 diabetes. Availability and indications may vary by region; check local labeling and discuss with your healthcare provider.

What Comes with the Minimed 780G System?

When purchasing the system, users receive:

The MiniMed 780G insulin pump
Guardian 4 CGM and transmitter
Infusion sets
User guides and comprehensive training resources to ensure confident usage.

Infusion Set

Medtronic Extended infusion set

CGM Compatibility

The MiniMed 780G is compatible with the Guardian™ 4 CGM. In 2025, Medtronic also announced and received U.S. clearances enabling additional sensor options: the Simplera Sync™ patch iCGM for 780G and a pathway for integration with Abbott’s Instinct™ sensor designed explicitly for MiniMed integration. Availability may depend on market rollout and labeling; check with Medtronic and your clinic for the most current options.

Mobile Apps for Control and Monitoring

The MiniMed™ Mobile app allows users to monitor glucose levels, pump data, and insulin information via smartphones and smartwatches. The CareLink™ Connect app provides caregivers and healthcare providers with remote access to the user’s glucose and insulin delivery data for seamless support (up to five care partners).

Battery and Maintenance

The system features a rechargeable battery that lasts several days on a single charge, making it convenient for daily use. Users should charge the pump regularly to ensure uninterrupted functionality.

Pros and Cons

Pros:

automated insulin adjustments, including auto-corrections
customizable glucose targets and adjustable AIT
real-time monitoring features and remote sharing
7-day infusion set option reduces change burden
water-resistant design

Cons:

Some users note that regular maintenance, such as changing sensors and infusion sets, is required.
Initial setup may feel overwhelming.

The Medtronic MiniMed 780G System represents a transformative step in diabetes management, offering advanced automation and customization to meet individual needs. For people with type 1 diabetes—and now many adults with insulin-requiring type 2 diabetes—this system can provide peace of mind and improved glucose control. To learn more, visit Medtronic’s official website or consult with your healthcare provider.

Last Updated on January 28, 2026

Authors

John Walsh, PA, CDTC

John Walsh, PA is a Physician Assistant and Diabetes Clinical Specialist with Advanced Metabolic Care and Research. He has provided clinical care for patients with diabetes for more than 30 years, including thousands of people on insulin pumps. He is the co-author of Pumping Insulin, now in its 6th edition, Using Insulin, STOP the Rollercoaster, and The Pocket Pancreas. President of the Diabetes Mall, he is also the webmaster of diabetesnet.com, a highly trafficked source of diabetes information and technology, and opensourcediabetes.org. John is a consultant and advisory board member for pharmaceutical and device corporations and a frequent speaker on diabetes, insulin pump therapy, bolus calculators, infusion set design, glucose management, and the future of smart pumps, meters, and continuous monitors. His recent research, published in the Journal of Diabetes Science and Technology, explores the dosing and behaviors that lead to successful glucose outcomes by pump wearers. John has worn nearly every insulin pump and CGM available and is a sub-investigator on numerous research studies on diabetes drugs and devices.
Ruth Roberts, MA

Ruth Roberts, MA, is a medical writer, editor, and educational consultant on intensive self-management. She has been involved in diabetes support groups for over 20 years and has co-authored several books on the subject of diabetes. She is a professional member of the American Diabetes Association and has served on the Board of Directors for the International Diabetes Athletes Association. She manages business matters and product development for the company. Her expertise in presenting complex information in a clear, easy-to-read format benefits our publications. She worked for 20 years in academic teaching and corporate training before developing the company.